| Paulina Mejia Durant, | |
|
901 S Campbell St, El Paso, TX 79901-3325 | |
| (915) 276-3749 | |
| Not Available |
| Full Name | Paulina Mejia Durant |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 901 S Campbell St, El Paso, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013688589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 112456 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Paulina Mejia Durant, 901 S Campbell St, El Paso, TX 79901-3325 Ph: () - | Paulina Mejia Durant, 901 S Campbell St, El Paso, TX 79901-3325 Ph: (915) 276-3749 |
News Archive
Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.
A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Human geneticists can now see which variations on the human genome are inherited together, thanks to a new way of viewing genetic variations in the latest release of the Ensembl genome browser [a joint project between EMBL's EBI and the Wellcome Trust Sanger Institute].
› Verified 6 days ago
Edsol Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6405 Kiowa Ct, El Paso, TX 79925 Phone: 915-771-0703 Fax: 915-771-0703 | |
Mrs. Jeanette B. Lopez, MA; CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1510 N Zaragoza Rd, Ste. A-11, El Paso, TX 79936 Phone: 915-855-0601 Fax: 915-855-0751 | |
Natalya D Rich, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1101 E Schuster Ave, El Paso, TX 79902 Phone: 915-544-8484 Fax: 833-272-3454 | |
Bryanna Amanda Michel, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9600 Sims Dr, El Paso, TX 79925 Phone: 915-434-9000 | |
Irene Teran, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7500 Viscount Blvd, Suite C-49, El Paso, TX 79925 Phone: 915-838-7604 | |
Mrs. Cindy Jean Price-norton, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6666 Morrill Rd, El Paso, TX 79932 Phone: 915-877-5602 Fax: 915-877-7308 | |
Vanesa P Smith, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1477 Lomaland Dr Ste E7, El Paso, TX 79935 Phone: 915-599-6690 Fax: 915-592-7168 |